Skip to main content

Table 1 Effect of progesterone, MPA, and NOMAC on the uterine weight in estradiol-benzoate-treated mice

From: Preclinical pharmacological profile of nomegestrol acetate, a synthetic 19-nor-progesterone derivative

Estradiol benzoate Progestogen Dose No. of mice Uterine weight
(mg/mouse/3 days)
Subcutaneous administration a
20 21.61 ± 1.37**
0.1 10 32.88 ± 2.26
0.1 Progesterone 0.3 5 32.04 ± 1.38
0.1 0.6 5 30.46 ± 1.53
0.1 0.9 5 29.78 ± 2.99
0.1 MPA 0.3 5 27.50 ± 1.08
0.1 0.6 5 24.92 ± 2.37*
0.1 0.9 5 29.34 ± 2.42
0.1 NOMAC 0.3 5 27.16 ± 3.22
0.1 0.6 5 23.72 ± 1.08**
0.1 0.9 5 23.94 ± 1.16**
Oral administration a
40 12.31 ± 0.49
0.1 31 40.99 ± 2.11
0.1 MPA 0.3 8 30.08 ± 3.92*
0.1 0.6 7 22.39 ± 3.09**
0.1 0.9 8 24.70 ± 2.27**
0.1 NOMAC 0.1 9 46.74 ± 4.48
0.1 0.3 16 29.22 ± 1.89**
0.1 0.6 28 30.97 ± 2.47**
0.1 0.9 16 25.07 ± 2.28**
0.1 1.8 9 25.09 ± 4.37**
  1. Uterine weights (mg) are expressed as the mean ± standard deviation.
  2. aEstradiol-benzoate was administered as a subcutaneous injection. MPA, medroxyprogesterone acetate. * P<0.01; ** P<0.001 compared with the estradiol-benzoate-treated control group.